Answers are grounded in this paper and cite their sources.
Targeting CD38 via daratumumab is a new promising therapeutic option in therapy refractory autoimmune diseases. Efficacy as well as optimal therapeutic regimen and management or prevention of adverse events require further investigation. Therefore, systematic clinical trials of this therapeutic approach are needed.
No takes yet. Share an insight, caveat, or question.
Holzer et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: